Overview

Update
Acquisitions
1 Acquisition
IPO / Stock
Went Public on Nov 25, 2015 / EBR:TIG
Headquarters:
Leuven, Vlaams-Brabant
Description:
TiGenix is a biomedical company focused on research and development of innovative local treatments for damaged and osteoarthritic joints.
Founders:
, ,
Categories:
Biotechnology, Clinical Trials, Medical
Website:
http://www.tigenix.com
Social:

Company Details

Update

TiGenix NV/SA (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.

Funding Rounds (6) - $68.29M

Update
DateAmount / RoundValuationLead InvestorInvestors
Nov, 2015€8.7M / Private Equity0
Dec, 2013$13.7M / Debt Financing1
Nov, 2013€12M / Private Equity0
Jul, 2013€6.5M / Private Equity0
Jun, 2009$7.5M / Private Equity2
Oct, 2003€12M / Venture2

Acquisitions (1)

Update
DateAcquiredAmount
Nov 30, 2011Stock

Current Team (6)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Office

    Haasrode Researchpark 1724

    Romeinse straat 12 bus 2

    Leuven, Vlaams-Brabant 3001

    Belgium

Past Team (2)

Update

Images (1)

Update

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos